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Case Synopsis 
A 69-year-old man, a smoker with a history of 
untreated hepatitis C and type II diabetes mellitus, 
presented to the emergency department at NYU 
Langone Tisch Hospital for a blistering eruption of 
several months’ duration. The patient reported a 
long-time history of "marks" on his forearms and 
hands. However, he had never blistered until two 
months prior. He noted worsening of symptoms in 
the week leading up to presentation with increasing 
number of blisters on his dorsal hands and forearms, 
followed by progression to involve his left cheek, ear,  
and neck (Figure 1). The eruption was associated 
with pruritus and a burning sensation. He noted 
frequent usage of his hands at work in printing for 
the police force and through hobbies, which 
included gardening and home-improvement. He 
denied a history of increased hair growth on the face. 
New medications included varenicline, which he had 
started several weeks prior in the setting of smoking 
cessation and tramadol for joint pain. He admitted to 
“cheating” with smoking cessation and having 
several cigarettes daily. Out of concern that this 
might be a drug reaction, he stopped all medications 
a couple of weeks prior to presentation. He denied a 
family history of similar lesions. A review of systems 
revealed frequent dark urine (which at times 
resolved with hydration), chronic joint pain, and 
Raynaud phenomenon. He denied a history of 
alcohol use or human immunodeficiency virus. 
On examination, the patient was well appearing and 
in no acute distress. His vital signs were within 
normal limits. On the forehead, lateral cheeks, left 
ear, and left posterolateral neck there were scattered 
superficial erosions, many with heme-crust. 
Scattered on the dorsal aspect of his forearms and 
hands were multiple hypopigmented, atrophic scars, 
scattered heme-crusted erosions, and non-
inflammatory, tense vesicles and bullae of varied 
sizes (Figure 2). There were a few firm, white, pearly 
papules consistent with milia. There was mild 
hypertrichosis overlying the lateral cheeks. The 
remainder of the full body skin examination was 
within normal limits. 
Abstract 
Porphyria cutanea tarda (PCT) is the most common 
type of porphyria, presenting in middle-aged 
patients with a photodistributed vesiculobullous 
eruption, milia, and scars. Porphyria cutanea tarda 
occurs in relation to inhibition of uroporphyrinogen 
decarboxylase, a key enzyme in the heme 
biosynthesis pathway. A number of genetic and 
acquired factors increase susceptibility to PCT by 
reducing uroporphyrinogen decarboxylase activity. 
A handful of other vesiculobullous conditions may 
mimic PCT both clinically and histologically; 
therefore, both skin biopsy and laboratory evaluation 
are helpful in confirming the diagnosis. We report a 
case of PCT in the setting of cigarette usage and 
untreated hepatitis C infection. 
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A complete blood count demonstrated a 
hemoglobin of 13.0g/dL (ref 13.7-17.5g/dL), 
hematocrit of 38.5% (ref 40-51%), normal white 
blood count, platelet count, and normal differential. 
An erythrocyte sedimentation rate was 81mm/hr (ref 
0-10mm/hr), and a C-reactive protein level was 
20.9mg/L (1-5mg/L). A urine fractionated porphyrin 
test revealed elevated concentrations of urine 
uroporphyrin, heptacarboxylate porphyrin, and 
pentacarboxyl porphyrins. A total plasma/serum 
porphyrin level was elevated at 669nmol/L (ref 0-
15nmol/L). 
Two 4mm punch biopsies of the left dorsal hand 
were obtained. There was a pauci-inflammatory 
subepidermal blister with festooning and hyalinized 
papillary dermal vessels (Figure 3). Direct 
immunofluorescence showed perivascular C3 
(Figure 4) and IgM deposition. IgA, IgG, and 
fibrinogen were negative. 
 
Case Discussion 
Porphyria cutanea tarda (PCT) is the most common 
type of porphyria, a disorder of heme synthesis [1]. 
Enzyme defects along the heme synthesis pathway 
lead to the buildup of pathway precursors, causing 
two types of porphyrias: acute hepatic porphyrias 
and photocutaneous porphyrias [1]. The cutaneous 
porphyrias have skin involvement related to 
overproduction of photosensitizing porphyrins [1]. 
In the case of PCT, uroporphyrinogen decarboxylase 
is inhibited, leading to a buildup of photosensitizing 
porphyrins produced by the liver [1, 2]. In nearly all 
patients with clinical disease, at least two genetic or 
acquired factors that reduce uroporphyrinogen 
decarboxylase activity, and thus increase 
susceptibility to PCT, are present [3]. Genetic factors 
include hemochromatosis (prevalence 53%) and 
uroporphyrinogen decarboxylase mutation (17%), 
whereas acquired factors include hepatitis C virus 
(HCV) infection (69%), alcohol consumption (87%), 
tobacco use (81%), estrogen use in female patients 
(66%), and human immunodeficiency virus infection 
(13%) [3]. Our patient had active hepatitis C infection 
and was a smoker undergoing smoking cessation. 
Porphyria cutanea tarda is most often seen in the 
middle-aged population, classically with a 
photodistributed vesiculobullous eruption that 
heals with scars and milia [2]. Hypertrichosis may be 
seen and in advanced disease, sclerodermoid 
features may also be present [2]. In order to diagnose 
PCT, urine or plasma porphyrin profiles should be 
obtained, which will reveal a predominance of 
uroporphyrin and heptacarboxyl porphyrin [1]. 
Skin biopsy for both hematoxylin and eosin as well as 
direct immunofluorescence is also helpful to 
distinguish PCT from other blistering disorders [2]. 
On histopathology, the subepidermal bulla is 
characteristically cell-poor and there is festooning of 
the dermal papillae, likely caused by the perivascular 
and vascular deposition of glycoproteins in the 
superficial dermis [2]. Direct immunofluorescence 
(DIF) microscopy reveals superficial and perivascular 
Immunoglobulin G (IgG) more often than IgM, 
complement, and fibrinogen [2]. Historically, the 
urine was examined by both natural light and Wood 
lamp — after several hours of exposure to natural 
light the urine turns red to brown, and on exposure 
 
Figure 1. Forehead, lateral cheek, left ear, and left posterolateral 
neck with scattered superficial erosions, many with heme-crust. 
Lateral cheek with mild hypertrichosis. 
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to UVA, the urine fluoresces pink to red [2]. This 
technique fell out of favor owing to lack of sensitivity 
and specificity for PCT [2]. 
The differential diagnosis for PCT includes other 
vesiculobullous disorders, especially those with a 
predilection for photodistributed sites. 
Pseudoporphyria, which may be idiopathic or seen in 
the setting of certain medications (commonly 
nonsteroidal anti-inflammatory drugs), appears 
similarly clinically and is identical on histopathology; 
however, these patients will have normal porphyrin 
levels [1, 2, 4]. The non-inflammatory type of 
epidermolysis bullosa acquisita (EBA) commonly 
affects trauma-prone acral surfaces and may also 
heal with scars and milia [5, 6]. Histologically, EBA 
similarly is characterized by cell-poor subepidermal 
bullae and DIF demonstrates deposition of IgG at the 
basement membrane zone [6]. Bullous pemphigoid 
(BP) should be considered in the setting of tense 
bullae. However, classically bullae of BP may be seen 
on non-sun exposed sites and often there is an 
urticarial phase that precedes the formation of bullae 
[7]. Bullous systemic lupus erythematosus was  
considered in this patient with a history of Raynaud 
phenomenon; however, he lacked other features of 
lupus erythematosus. The characteristic clinical 
features of bullous systemic lupus erythematosus 
include widespread bullae that heal without scars or 
milia and histologic features of the subepidermal 
bullae of systemic lupus are distinctive with a 
neutrophil-predominant infiltrate and distinctive 
immunoreactants on DIF [8]. Porphyrin studies may 
be helpful to differentiate PCT from the above when 
the diagnosis is otherwise unclear. 
In distinguishing amongst the porphyrias with 
cutaneous phenotype, it may be helpful to first 
group those that are classically seen in children 
versus adults. Hepatoerythropoeitic porphyria, 
congenital erythropoietic porphyria, and 
erythropoietic protoporphyria present in childhood. 
The cutaneous porphyrias that do not present in 
childhood include hereditary coproporphyria (HCP) 
and variegate porphyria (VP), in addition to PCT. 
Variegate porphyria has an onset in adolescence or 
adulthood with blisters and acute systemic attacks.  
 
Figure 2. Dorsal aspect of hand with multiple hypopigmented, 
atrophic scars, scattered heme-crusted erosions, non-
inflammatory, tense vesicles, and few firm white, pearly papules 
consistent with milia. 
 
Figure 3. Biopsy of the left dorsal hand with H&E stain revealed a 
pauci-inflammatory subepidermal blister at A) 40×, with 
festooning and hyalinized papillary dermal vessels at 200×, B). 
A
B
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Characteristically, the plasma fluoresces pink at an 
emission peak of 626nm in symptomatic patients. 
HCP has similar clinical presentation to VP and the 
distinguishing feature is the high level of 
copropoporphyrin in the stool. 
Treatment of PCT includes treatment of the 
underlying triggering medical conditions, removal of 
precipitating factors, usage of oral anti-malarial 
medications, or hepatic iron depletion through 
phlebotomy [1, 9]. Antimalarials are effective owing  
to their action within hepatocytes to free porphyrins, 
which are then renally excreted [1]. With the recent 
advent of direct-acting antivirals for HCV, the 
treatment of HCV has been revolutionized and the 
vast majority of patients with HCV have the ability to 
achieve cure. Several case studies have 
demonstrated the resolution of PCT clinical 
symptoms following treatment of HCV with direct-
acting antivirals [10, 11, 12].  
Once the diagnosis was made for our patient, he was 
referred to the hepatology clinic for the treatment of 
HCV. He was also referred to the hematology clinic 
for further evaluation and co-management. The 
possibility of treatment with hydroxychloroquine 
and phlebotomy was discussed. However, treatment 
was deferred until his hepatitis had been treated. The 
patient was extensively counseled on strict photo-
protective behaviors, complete smoking cessation, 
and the avoidance of iron-rich foods, alcohol, and 
hepatotoxic medications. He demonstrated 
significant improvement at his three-week follow-up 
visit and sustained improvement 6 months later. 
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Figure 4. Direct immunofluorescence showed perivascular C3 
deposition at 20×. 
